Recent advances in targeting the fatty acid biosynthetic pathway using fatty acid synthase inhibitors

References

• Menendez JA, Lupu R. Fatty acid and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007;7:763–777. DOI:10.1038/nrc2222
   PubMed Web of Science ®Google Scholar
• Abramson HN. The lipogenesis pathway as a cancer target. J Med Chem. 2011;54:5615–5638. DOI:10.1021/jm2005805.
   PubMed Web of Science ®Google Scholar
• Kridel SJ, Lowther WT, Pemble CW IV. Fatty acid inhibitors: new directions for oncology. Expert Opin Investig Drugs. 2007;15:1817–1829. DOI:10.1517/13543784.16.11.1817
   Web of Science ®Google Scholar
• Menendez JA, Vazquez-Martin A, Ortega FJ, et al. Fatty acid synthase: association with insulin resistance, type 2 diabetes and cancer. Clin Chem. 2009;55:425–438. DOI:10.1373/clinchem.2008.115352 .
   PubMed Web of Science ®Google Scholar
• Flavin R, Peluso S, Nguyen PL, et al. Fatty acid synthase as a potential target in cancer. Future Oncol. 2010;6:551–562. DOI:10.2217/fon.10.11
   PubMed Web of Science ®Google Scholar
• Maier T, Leibundgut M, Boehringer D, et al. Structure and function of eukaryotic fatty acid synthases. Q Rev Biophys. 2010;43:373–422. DOI:10.1017/S0033583510000156
   PubMed Web of Science ®Google Scholar
• Maier T, Jenni S, Ban N. Architecture of mammalian fatty acid synthase at 4.5 Å resolution. Science. 2006;311:1258–1262. DOI:10.1126/science.1123248
   PubMed Web of Science ®Google Scholar
• Leibundgut M, Maier T, Jenni S, et al. The multienzyme architecture of eukaryotic fatty acid synthases. Curr Opin Struct Biol. 2008;18:714–725. DOI:10.1016/j.sbi.2008.09.008
   PubMed Web of Science ®Google Scholar
• Smith S. The animal fatty acid synthase: one gene, one polypeptide, seven enzymes. FASEB J. 1994;8:1248–1259.
   PubMed Web of Science ®Google Scholar
• Smith S, Witkowski A, Joshi AK. Structural and functional organization of the animal fatty acid synthase. Prog Lipid Res. 2003;42:289–317. DOI:10.1016/S0163-7827(02)00067-X
   PubMed Web of Science ®Google Scholar
• Chirala SS, Wakil SJ. Structure and function of animal fatty acid synthase. Lipids. 2004;39:1045–1053.
   PubMed Web of Science ®Google Scholar
• Asturias FJ. Mammalian fatty acid synthase: X-ray structure of a molecular assembly line. ACS Chem Biol. 2006;1:135–138. DOI:10.1021/cb6001448
   PubMed Web of Science ®Google Scholar
• Yoshii Y, Furukawa T, Oyama N, et al. Fatty acid synthase is a key target in multiple essential tumor functions of prostate cancer: uptake of radiolabeled acetate as a predictor of the targeted therapy outcome. PLoS ONE. 2013;8:e64570. DOI:10.1371/journal.pone.0064570
   PubMed Web of Science ®Google Scholar
• Chen H-W, Chang Y-F, Chuang H-Y, et al. Targeted therapy with fatty acid synthase inhibitors in a human prostate carcinoma LNCaP/tk-luc-bearing animal model. Prostate Cancer Prostatic Dis. 2012;15:260–264. DOI:10.1038/pcan.2012.15
   PubMed Web of Science ®Google Scholar
• Zaytseva YY, Rychahou PG, Gulhati P, et al. Inhibition of fatty acid synthase attenuates CD44-associated signaling and reduces metastasis in colorectal cancer. Cancer Res. 2012;72:1–13. DOI:10.1158/0008-5472.CAN-11-4057
   Web of Science ®Google Scholar
• Orita H, Coulter J, Lemmon C, et al. Selective inhibition of fatty acid synthase for lung cancer treatment. Clin Cancer Res. 2007;13:7139–7145. DOI:10.1158/1078-0432.CCR-07-1186
   PubMed Web of Science ®Google Scholar
• Menendez JA, Lupu R. RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells. Intl J Mol Med. 2005;15:33–40.
   PubMed Web of Science ®Google Scholar
• Pizer ES, Wood FD, Heine HS, et al. Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. Cancer Res. 1996;56:1189–1193.
   PubMed Web of Science ®Google Scholar
• Pizer ES, Jackisch C, Wood FD, et al. Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells. Cancer Res. 1996;56:2745–2747.
   PubMed Web of Science ®Google Scholar
• Liu ZL, Zhou Y, Luo QF, et al. Inhibition of fatty acid synthase suppresses osteosarcoma cell invasion and migration. Indian J Pathol Microbio. 2012;55:163–169. DOI:10.4103/0377-4929.97849
   PubMed Web of Science ®Google Scholar
• Liu ZL, Wang G, Peng AF, et al. Fatty acid synthase expression in osteosarcoma and its correlation with pulmonary metastasis. Oncol Lett. 2012;4:878–882. DOI:10.3892/ol.2012.862
   PubMed Web of Science ®Google Scholar
• Gelebart P, Zak Z, Anand M, et al. Blockade of fatty acid synthase triggers significant apoptosis in mantle cell lymphoma. PLoS ONE. 2012;7;e33738.
   PubMed Web of Science ®Google Scholar
• Fritz V, Benfodda Z, Henriquet C, et al. Metabolic intervention on lipid synthesis converging pathways abrogates prostate cancer growth. Oncogene. 2013;32:5101–5110. DOI:10.1038/onc.2012.523
   PubMed Web of Science ®Google Scholar
• Pizer ES, Chrest FJ, DiGiuseppe JA, et al. Pharmacological inhibitors of mammalian fatty acid synthase suppress DNA replication and induce apoptosis in tumor cell lines. Cancer Res. 1998;58:4611–4615.
   PubMed Web of Science ®Google Scholar
• Ho TS, Ho YP, Wong WY, et al. Fatty acid synthase inhibitors cerulenin and C75 retard growth and induce caspase-dependent apoptosis in human melanoma A-375 cells. Biomed Pharmacother. 2007;61:578–587. DOI:10.1016/j.biopha.2007.08.020
   PubMed Web of Science ®Google Scholar
• Bandyopadhyay S, Zhan R, Wang Y, et al. Mechanism of apoptosis induced by the inhibition of fatty acid synthase in breast cancer cells. Cancer Res. 2006;66:5934–5940. DOI:10.1158/0008-5472.CAN-05-3197
   PubMed Web of Science ®Google Scholar
• Flegal KM, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA. 2012;307:491–497.
   PubMed Web of Science ®Google Scholar
• Ogden CL, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999–2010. JAMA. 2012;307:483–490. DOI:10.1001/jama.2012.40
   PubMed Web of Science ®Google Scholar
• Wang D, DuBois RN. Association between obesity and cancer: the role of fatty acid synthase. J Natl Cancer Inst. 2012;104:1–3. DOI:10.1093/jnci/djs010
   Google Scholar
• Mathes WF, Kelly SA, Pomp D. Advances in comparative genetics: influence of genetics on obesity. Br J Nutr. 2011;106(suppl 1):S1–S10. DOI:10.1017/S0007114511001905
   Google Scholar
• Berndt J, Kovacs P, Ruschke K, et al. Fatty acid synthase gene expression in human adipose tissue: association with obesity and type 2 diabetes. Diabetologia. 2007;50:1472–1480. DOI:10.1007/s00125-007-0689-x
   PubMed Web of Science ®Google Scholar
• Migita T, Ruiz S, Fornari A, et al. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst. 2009;101:519–532. DOI:10.1093/jnci/djp030
   PubMed Web of Science ®Google Scholar
• Martinez-Useros J, Garcia-Foncillas J. Obesity and colorectal cancer: molecular features of adipose tissue. J Transl Med. 2016;14:21. DOI:10.1186/s12967-016-0867-z
   PubMed Web of Science ®Google Scholar
• Aleman JO, Eusebi LH, Ricciardiello L, et al. Mechanisms of obesity-induced gastrointestinal neoplasia. Gastroenterology. 2014;146:357–373. DOI:10.1053/j.gastro.2013.11.051
   PubMed Web of Science ®Google Scholar
• Swierczynski J, Goyke E, Wach L, et al. Comparative study of the lipogenic potential of human and rat adipose tissue. Metabolism. 2000;49:594–599.
   PubMed Web of Science ®Google Scholar
• Guichard C, Dugail I, Liepvre L, et al. Genetic regulation of fatty acid synthetase expression in adipose tissue: overtranscription of the gene in genetically obese rats. J Lipid Res. 1992;33:679–687.
   PubMed Web of Science ®Google Scholar
• Liu LH, Wang XK, Hu YD, et al. Effects of a fatty acid synthase inhibitor on adipocyte differentiation of mouse 3T3-L1 cells. Acta Pharmacol Sin. 2004;25:1052–1057.
   PubMed Web of Science ®Google Scholar
• Lodhi I, Yin L, Jensen-Urstad APL, et al. Inhibiting adipose tissue lipogenesis reprograms thermogenesis and PPARγ activation to decrease diet-induced obesity. Cell Metabolism. 2012;16:189–201. DOI:10.1016/j.cmet.2012.06.013
   PubMed Web of Science ®Google Scholar
• Shimokawa T, Kumar MV, Lane MD. Effect of fatty acid synthase inhibitor on food intake and expression of hypothalamic neuropeptides. Proc Natl Acad Sci USA. 2002;99:66–71. DOI:10.1073/pnas.012606199
   PubMed Web of Science ®Google Scholar
• Lopez M, Tovar S, Vazquez J, et al. Sensing the fat: fatty acid metabolism in the hypothalamus and the melanocortin system. Peptides. 2005;26:1753–1758. DOI:10.1016/j.peptides.2004.11.025
   PubMed Web of Science ®Google Scholar
• Clegg DJ, Wortman MD, Benoit SC, et al. Comparison of central and peripheral administration of C75 on food intake, body weight and conditioned taste aversion. Diabetes. 2002;5:3196–3201. DOI:10.2337/diabetes.51.11.3196
   Web of Science ®Google Scholar
• Hu Z, Cha SH, Chohnan S, et al. Hypothalamic malonyl-CoA as a mediator of feeding behavior. Proc Natl Acad Sci USA. 2003;100:12624–12629. DOI:10.1073/pnas.1834402100
   PubMed Web of Science ®Google Scholar
• Gao S, Moran TH, Lopaschuk GD, et al. Hypothalamic malonyl-CoA and the control of food intake. Physiol Behav. 2013;122:17–24. DOI:10.1016/j.physbeh.2013.07.014
   PubMed Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the study of liver diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–2023. DOI:10.1002/hep.25762
   PubMed Web of Science ®Google Scholar
• Takaki A, Kawai D, Yamamoto K. Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH). Intl J Mol Sci. 2014;15:7352–7379. DOI:10.3390/ijms15057352
   PubMed Web of Science ®Google Scholar
• Tacer KF, Rozman D. Nonalcoholic fatty liver disease: focus on lipoprotein and lipid deregulation. J Lipids. 2011;2011:783976.
   PubMedGoogle Scholar
• Marchesini G, Brizi M, Blanchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50:1844–1850.
   PubMed Web of Science ®Google Scholar
• Koo S-H. Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis. Clin Mol Hepatol. 2013;19:210–215. DOI:10.3350/cmh.2013.19.3.210
   PubMedGoogle Scholar
• Musso G, Cassader M, Gambino R. Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. Nat Rev Drug Discov. 2016;15:249–274. DOI:10.1038/nrd.2015.3
   PubMed Web of Science ®Google Scholar
• Jensen-Urstad APL, Semenkovich CF. Fatty acid synthase and liver triglyceride metabolism: housekeeper or messenger? Biochim Biophys Acta. 2012;1821:747–753. DOI:10.1016/j.bbalip.2011.09.017
   PubMed Web of Science ®Google Scholar
• Dorn C, Riener M-O, Kirovski G, et al. Expression of fatty acid synthase in nonalcoholic fatty liver disease. Int J Clin Exp Pathol. 2010;3:505–514.
   PubMed Web of Science ®Google Scholar
• Mullen GE, Yet L. Progress in the development of fatty acid synthase inhibitors as anticancer targets. Bioorg Medchem Lett. 2015;25:4363–4369. DOI:10.1016/j.bmcl.2015.08.087
   PubMed Web of Science ®Google Scholar
• Pandey PR, Liu W, Xing F, et al. Anti-cancer drugs targeting fatty acid synthase (FAS). Recent Pat Anticancer Drug Discov. 2012;7:185–197.
   PubMed Web of Science ®Google Scholar
• Vazquez MJ, Leavens W, Liu R, et al. Discovery of GSK837149A, an inhibitor of human fatty acid synthase targeting the β-ketoacyl reductase reaction. Febs J. 2008;275:1556–1567. DOI:10.1111/j.1742-4658.2008.06314.x
   PubMed Web of Science ®Google Scholar
• Turrado C, Puig T, García-Cárceles J, et al. New synthetic inhibitors of fatty acid synthase with anticancer activity. J Med Chem. 2012;55:5013–5023. DOI:10.1021/jm2016045
   PubMed Web of Science ®Google Scholar
• Kley JT, Mack J, Hamilton B, et al. Discovery of BI 99179, a potent and selective inhibitor of type I fatty acid synthase with central exposure. Bioorg Medchem Lett. 2011;21:5924–5927.
   PubMed Web of Science ®Google Scholar
• Oslob JD, Johnson RJ, Cai H, et al. Imidazopyridine-based fatty acid synthase inhibitors that show anti-HCV activity and in vivo target modulation. ACS Medchem Lett. 2013;4:113–117. DOI:10.1021/ml300335r
   PubMed Web of Science ®Google Scholar
• Brenner AJ, Von Hoff DD, Infante JR, et al. First-in-human investigation of the oral first-in-class fatty acid synthase (FASN) inhibitor TVB-2640. J Clin Oncol. 2015;33(May 20 Supplement):TPS2615.
   Google Scholar
• Vance D, Goldberg I, Mitsuhashi O, et al. Inhibition of fatty acid synthetases by the antibiotic cerulenin. Biochem Biophys Res Commun. 1972;48:649–656.
   PubMed Web of Science ®Google Scholar
• Omura S. The antibiotic cerulenin, a novel tool for biochemistry as an inhibitor of fatty acid synthesis. Bacteriol Rev. 1976;40:681–697.
   PubMedGoogle Scholar
• Funabashi H, Kawaguchi A, Tomoda H, et al. Binding site of cerulenin in fatty acid synthetase. J Biochem. 1989;105:751–755.
   PubMed Web of Science ®Google Scholar
• Johansson P, Wiltschi B, Kumari P, et al. Inhibition of the fungal fatty acid synthase type I multienzyme complex. Proc Natl Acad Sci USA. 2008;105:12803–12808. DOI:10.1073/pnas.0805827105
   PubMed Web of Science ®Google Scholar
• Liu H, Liu J-Y, Wu X, et al. Biochemistry, molecular biology, and pharmacology of fatty acid synthase, an emerging therapeutic target and diagnosis/prognosis marker. Int J Biochem Mol Biol. 2010;1:69–89.
   PubMedGoogle Scholar
• Lupu R, Menendez JA. Pharmacological inhibitors of fatty acid synthase (FASN)—catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents? Curr Pharm Biotechnol. 2006;7:483–493. DOI:10.2174/138920106779116928
   PubMed Web of Science ®Google Scholar
• Kuhajda FP, Pizer ES, Li JN, et al. Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc Natl Acad Sci USA. 2000;97:3450–3454. DOI:10.1073/pnas.97.7.3450 .
   PubMed Web of Science ®Google Scholar
• Pappenberger G, Benz J, Gsell B, et al. Structure of the human fatty acid synthase KS-MAT didomain as a framework for inhibitor design. J Mol Biol. 2010;397:508–519. DOI:10.1016/j.jmb.2010.01.058
   PubMed Web of Science ®Google Scholar
• Wang X, Lin J, Chen Y, et al. Novel fatty acid synthase (FAS) inhibitors: design, synthesis, biological evaluation, and molecular docking studies. Bioorg Med Chem. 2009;17:1898–1904. DOI:10.1016/j.bmc.2009.01.050
   PubMed Web of Science ®Google Scholar
• Rendina AR, Cheng D. Characterization of the inactivation of rat fatty acid synthase by C75: inhibition of partial reactions and protection by substrates. Biochem J. 2005;388:895–903. DOI:10.1042/BJ20041963 .
   PubMed Web of Science ®Google Scholar
• Cheng F, Wang Q, Chen M, et al. Molecular docking study of the interactions between the thioesterase domain of human fatty acid synthase and its ligands. Proteins. 2008;70:1228–1234. DOI:10.1002/prot.21615
   PubMed Web of Science ®Google Scholar
• Wang X, Zhao G, Chen Y, et al. 1-Oxo-3-substitute-isothiochroman-4-carboxylic acid compounds: synthesis and biological activities of FAS inhibition. Bioorg Medchem Lett. 2009;19:770–772. DOI:10.1016/j.bmcl.2008.12.010
   PubMed Web of Science ®Google Scholar
• McFadden JM, Medghalchi SM, Thupari JN, et al. Application of a flexible synthesis of (5R)-thiolactomycin to develop new inhibitors of type I fatty acid synthase. J Med Chem. 2005;48:946–961. DOI:10.1021/jm049494r
   PubMed Web of Science ®Google Scholar
• Kridel SJ, Axelrod F, Rozenkrantz N, et al. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res. 2004;53:2070–2075. DOI:10.1158/0008-5472.CAN-03-3645
   Web of Science ®Google Scholar
• Hadvary P, Sidler W, Meister W, et al. The lipase inhibitor tetrahydrolipstatin binds covalently to the putative active site serine of pancreatic lipase. J Biol Chem. 1991;266:2021–2027.
   PubMed Web of Science ®Google Scholar
• Ritchie MK, Johnson LC, Clodfelter JE, et al. Crystal structure and substrate specificity of human thioesterase 2: insights into the molecular basis for the modulation of fatty acid synthase. J Biol Chem. 2016;291:3520–3530. DOI:10.1074/jbc.M115.702597
   PubMed Web of Science ®Google Scholar
• Pemble CW, Johnson LC, Kridel SJ, et al. Crystal structure of the thioesterase domain of human fatty acid synthase inhibited by Orlistat. Nat Struct Mol Biol. 2007;14:704–709. DOI:10.1038/nsmb1265 .
   PubMed Web of Science ®Google Scholar
• Richardson RD, Ma G, Oyola Y, et al. Synthesis of novel beta-lactone inhibitors of fatty acid synthase. J Med Chem. 2008;51:5285–5296. DOI:10.1021/jm800321h
   PubMed Web of Science ®Google Scholar
• Purohit VC, Richardson RD, Smith JW, et al. Practical, catalytic, asymmetric synthesis of beta-lactones via a sequential ketene dimerization/hydrogenation process: inhibitors of the thioesterase domain of fatty acid synthase. J Org Chem. 2006;71:4549–4558. DOI:10.1021/jo060392d
   PubMed Web of Science ®Google Scholar
• Tian WX. Inhibition of fatty acid synthase by polyphenols. Curr Med Chem. 2006;13:967–977. DOI:10.2174/092986706776361012
   PubMed Web of Science ®Google Scholar
• Wang X, Tian W. Green tea epigallocatechin gallate: a natural inhibitor of fatty-acid synthase. Biochem Biophys Res Commun. 2001;288:1200–1206. DOI:10.1006/bbrc.2001.5923
   PubMed Web of Science ®Google Scholar
• Yang CS, Wang X, Lu G, et al. Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat Rev Cancer. 2009;9:429–439. DOI:10.1038/nrc2641
   PubMed Web of Science ®Google Scholar
• Wang X, Song KS, Guo QX, et al. The galloyl moiety of green tea catechins is the critical structural feature to inhibit fatty acid synthase. Biochem Pharmacol. 2003;66:2039–2047. DOI:10.1016/S0006-2952(03)00585-9
   PubMed Web of Science ®Google Scholar
• Prochaska HJ, Scotto KW. Use of flavonoids to treat multidrug resistant cancer cells. Sloan-Kettering Institute US 5336685. 1994
   Google Scholar
• Manach C, Scalbert A, Morand C, et al. Polyphenols: food sources and bioavailability. Am J Clin Nutr. 2004;79:727–747.
   PubMed Web of Science ®Google Scholar
• Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5:493–506. DOI:10.1038/nrd2060
   PubMed Web of Science ®Google Scholar
• Sadowski MC, Pouwer RH, Gunter JH, et al. The fatty acid synthase inhibitor triclosan: repurposing an anti-microbial agent for targeting prostate cancer. Oncotarget. 2014;5:9362–9381. DOI:10.18632/oncotarget.2433
   PubMed Web of Science ®Google Scholar
• Rodricks JV, Swenberg JA, Borzelleca JF, et al. Triclosan: a critical review of the experimental data and development of margins of safety for consumer products. Crit Rev Toxicol. 2010;40:422–484. DOI:10.3109/10408441003667514
   PubMed Web of Science ®Google Scholar
• Lu S, Archer MC. Fatty acid synthase is a potential molecular target for the chemoprevention of breast cancer. Carcinogenesis. 2005;26:153–157. DOI:10.1093/carcin/bgh278
   PubMed Web of Science ®Google Scholar
• Liu B, Wang Y, Fillgrove KL, et al. Triclosan inhibits enoyl-reductase of type I fatty acid synthase in vitro and is cytotoxic to MCF-7 and SKBr-3 breast cancer cells. Cancer Chemother Pharmacol. 2002;49:187–193. DOI:10.1007/s00280-001-0399-x
   PubMed Web of Science ®Google Scholar
• Fan H, Liang Y, Jiang B, et al. Curcumin inhibits intracellular fatty acid synthase and induces apoptosis in human breast cancer MDA-MB-231 cells. Oncol Rep. 2016;35:2651–2656. DOI:10.3892/or.2016.4682
   PubMed Web of Science ®Google Scholar
• Fan H, Wu D, Tian W, et al. Inhibitory effects of tannic acid on fatty acid synthase and 3T3-L1 preadipocyte. Biochim Biophys Acta. 2013;1831:1260–1266. DOI:10.1016/j.bbalip.2013.01.006
   PubMed Web of Science ®Google Scholar
• Li P, Tian W, Ma X. Alpha-mangostin inhibits intracellular fatty acid synthase and induces apoptosis in breast cancer cells. Mol Cancer. 2014;13:138. DOI:10.1186/1476-4598-13-138
   PubMed Web of Science ®Google Scholar
• Häbich D, von Nussbaum F. Platensimycin, a new antibiotic and superbug challenger from nature. ChemMedChem. 2006;1:951–954. DOI:10.1002/cmdc.200600145
   PubMed Web of Science ®Google Scholar
• Wu M, Singh SB, Wang J, et al. Antidiabetic and antisteatotic effects of the selective fatty acid synthase (FAS) inhibitor platensimycin in mouse models of diabetes. Proc Natl Acad Sci USA. 2011;108:5378–5383. DOI:10.1073/pnas.1002588108
   PubMed Web of Science ®Google Scholar
• Maier T, Leibundgut M, Ban N. The crystal structure of a mammalian fatty acid synthase. Science. 2008;321:1315–1322. DOI:10.1126/science.1161269
   PubMed Web of Science ®Google Scholar
• John A, Vetrivel U, Subramanian K, et al. Comparative docking of dual conformations in human fatty acid synthase thioesterase domain reveals potential binding cavity for virtual screening of ligands. J Biomol Struct Dyn. 2016;4:1–36.
   Google Scholar
• Hardwicke MA, Rendina AR, Williams SP, et al. A human fatty acid synthase inhibitor binds β-ketoacyl reductase in the keto-substrate site. Nat Chem Biol. 2014;10:774–779. DOI:10.1038/nchembio.1603 .
   PubMed Web of Science ®Google Scholar
• Hallman J, Laudeman C, Liu R, et al. Benzimidazoles as fatty acid synthase inhibitors. World Intellectual Property Organization WO2011056635. 2011.
   Google Scholar
• Anderson VE, Hammes GG. Stereochemistry of the reactions catalyzed by chicken liver fatty acid synthase. Biochemistry. 1984;23:2088–2094. DOI:10.1021/bi00304a033
   PubMed Web of Science ®Google Scholar
• Adams ND, Aquino CJ, Chaudhari AM, et al. Triazolones as fatty acid synthase inhibitors. World Intellectual Property Organization WO2011103546. 2011.
   Google Scholar
• Rivkin A, Kim YR, Goulet MT, et al. 3-Aryl-4-hydroxyquinolin-2(1H)-one derivatives as type I fatty acid synthase inhibitors. Bioorg Med Chem Lett. 2006;16:4620–4623. DOI:10.1016/j.bmcl.2006.06.014
   PubMed Web of Science ®Google Scholar
• de Melo EB. Multivariate SAR/QSAR of 3-aryl-4-hydroxyquinolin-2(1H)-one derivatives as type I fatty acid synthase (FAS) inhibitors. Eur J Med Chem. 2010;45:5817–5826. DOI:10.1016/j.ejmech.2010.09.044
   PubMed Web of Science ®Google Scholar
• Ventura R, Mordec K, Waszczuk J, et al. Inhibition of de novo palmitate synthesis by fatty acid synthase induces apoptosis in tumor cells by remodeling cell membranes, inhibiting signaling pathways, and reprogramming gene expression. EBioMedicine. 2015;2:806–822. DOI:10.1016/j.ebiom.2015.07.037
   PubMed Web of Science ®Google Scholar
• Yang W, Hood BL, Chadwick SL, et al. Fatty acid synthase is up-regulated during hepatitis C virus infection and regulates hepatitis C virus entry and production. Hepatology. 2008;48:1396−403. DOI:10.1002/hep.22508
   PubMed Web of Science ®Google Scholar
• Patel M, Infante J, Von Hoff D, et al. Report of a first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640. Poster CT203. AACR Metabolism and Cancer Conference; 2015 Jun 7–10; Bellevue, WA
   Google Scholar
• clinicaltrials.gov. A Phase 1, first-in-human study of escalating doses of oral TVB-2640 in patients with solid tumors. NCT02223247 2015.
   Google Scholar
• Abdel-Magid AF. Fatty acid synthase inhibitors as possible treatment for cancer. ACS Med Chem Lett. 2012;3:612−613. DOI:10.1021/ml3001566
   PubMed Web of Science ®Google Scholar
• Abdel-Magid AF. Fatty acid synthase (FASN) inhibitors as potential treatment for cancer, obesity, and liver related disorders. ACS Med Chem Lett. 2015;6:838–839. DOI:10.1021/acsmedchemlett.5b00143
   PubMed Web of Science ®Google Scholar
• Lu T, Alexander R, Bignan G, et al. Design and synthesis of a series highly potent and bioavailable FASN KR domain inhibitors for cancer. AACR Annual Meeting; 2014 Apr 5–9; San Diego, CA. Abst 4747.
   Google Scholar
• Alwarawrah Y, Hughes P, Loiselle D, et al. Fasnall, a selective FASN inhibitor, shows potent anti-tumor activity in the MMTV-Neu model of HER2+ breast cancer. Cell Chem Biol. 2016;23:1–11. DOI:10.1016/j.chembiol.2016.01.001
   PubMed Web of Science ®Google Scholar